Form 4 for EW Edwards Lifesciences
Accepted 2026-09-11 19:15:10 ET · period of report 2026-09-11 · accession 0001225208-26-007774 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-11 19:15 | 2026-09-11 | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $72.68 | +619 | 40.7K | +2% | +$45.0K |
| DT | 2026-09-11 19:15 | 2026-09-11 | EW | Lippis Daniel J. | CVP, TAVR | S - Sale+OE | $87.51 | -619 | 40.0K | -2% | -$54.2K |
| DT | 2026-09-11 19:15 | 2026-09-11 | EW | Lippis Daniel J. | CVP, TAVR | M - OptEx | $0.00 | -619 | 3,714 | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-11 | M | A | 619 | $72.68 | 40,652.91 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
| 2 | Common | Common Stock | 2026-09-11 | S | D | 619 | $87.51 | 40,033.91 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2026-09-11 | M | D | 619 | $0.00 | 3,714 | D | $72.68 · 2021-05-07 to 2027-05-06 | 619 Common Stock |